May 10, 2024 11:22 AM EDT
R&D
News Briefing

iTeos to raise $120M; Xbrane and STA­DA to out-li­cense Lu­cen­tis biosim­i­lar

ENDPOINTS

Plus, news about Anap­tys­Bio, Alza­mend, AEON Bio­phar­ma and ar­genx:

iTeos Ther­a­peu­tics’ $120M of­fer­ing: The im­muno-on­col­o­gy com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times